Unknown

Dataset Information

0

Risk-adapted dose-dense immunochemotherapy determined by interim FDG-PET in Advanced-stage diffuse large B-Cell lymphoma.


ABSTRACT: PURPOSE In studies of diffuse large B-cell lymphoma, positron emission tomography with [(18)F]fluorodeoxyglucose (FDG-PET) performed after two to four cycles of chemotherapy has demonstrated prognostic significance. However, some patients treated with immunochemotherapy experience a favorable long-term outcome despite a positive interim FDG-PET scan. To clarify the significance of interim FDG-PET scans, we prospectively studied interim FDG-positive disease within a risk-adapted sequential immunochemotherapy program. PATIENTS AND METHODS From March 2002 to November 2006, 98 patients at Memorial Sloan-Kettering Cancer Center received induction therapy with four cycles of accelerated R-CHOP (rituximab + cyclophosphamide, doxorubicin, vincristine, and prednisone) followed by an interim FDG-PET scan. If the FDG-PET scan was negative, patients received three cycles of ICE (ifosfamide, carboplatin, and etoposide) consolidation therapy. If residual FDG-positive disease was seen, patients underwent biopsy; if the biopsy was negative, they also received three cycles of ICE. Patients with a positive biopsy received ICE followed by autologous stem-cell transplantation. RESULTS At a median follow-up of 44 months, overall and progression-free survival were 90% and 79%, respectively. Ninety-seven patients underwent interim FDG-PET scans; 59 had a negative scan, 51 of whom are progression free. Thirty-eight patients with FDG-PET-positive disease underwent repeat biopsy; 33 were negative, and 26 remain progression free after ICE consolidation therapy. Progression-free survival of interim FDG-PET-positive/biopsy-negative patients was identical to that in patients with a negative interim FDG-PET scan (P = .27). CONCLUSION Interim or post-treatment FDG-PET evaluation did not predict outcome with this dose-dense, sequential immunochemotherapy program. Outside of a clinical trial, we recommend biopsy confirmation of an abnormal interim FDG-PET scan before changing therapy.

SUBMITTER: Moskowitz CH 

PROVIDER: S-EPMC3651601 | biostudies-literature | 2010 Apr

REPOSITORIES: biostudies-literature

altmetric image

Publications

Risk-adapted dose-dense immunochemotherapy determined by interim FDG-PET in Advanced-stage diffuse large B-Cell lymphoma.

Moskowitz Craig H CH   Schöder Heiko H   Teruya-Feldstein Julie J   Sima Camelia C   Iasonos Alexia A   Portlock Carol S CS   Straus David D   Noy Ariela A   Palomba Maria L ML   O'Connor Owen A OA   Horwitz Steven S   Weaver Sarah A SA   Meikle Jessica L JL   Filippa Daniel A DA   Caravelli James F JF   Hamlin Paul A PA   Zelenetz Andrew D AD  

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20100308 11


PURPOSE In studies of diffuse large B-cell lymphoma, positron emission tomography with [(18)F]fluorodeoxyglucose (FDG-PET) performed after two to four cycles of chemotherapy has demonstrated prognostic significance. However, some patients treated with immunochemotherapy experience a favorable long-term outcome despite a positive interim FDG-PET scan. To clarify the significance of interim FDG-PET scans, we prospectively studied interim FDG-positive disease within a risk-adapted sequential immuno  ...[more]

Similar Datasets

| S-EPMC10071786 | biostudies-literature
| S-EPMC7761146 | biostudies-literature
| S-EPMC7316220 | biostudies-literature
| S-EPMC4961236 | biostudies-literature
| S-EPMC6128083 | biostudies-literature
| S-EPMC4934532 | biostudies-literature
| S-EPMC6475957 | biostudies-literature
| S-EPMC7271579 | biostudies-literature
| S-EPMC7463417 | biostudies-literature
| S-EPMC3460598 | biostudies-literature